Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients.

Hartmann L, Haferlach C, Meggendorfer M, Nadarajah N, Kern W, Haferlach T, Stengel A.

Haematologica. 2019 Aug 1. pii: haematol.2019.227702. doi: 10.3324/haematol.2019.227702. [Epub ahead of print]

2.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL).

Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch I, Haferlach C, Kubicek S, Mayerhoefer M, Hopfinger G, Jaeger U, Dearden C.

Blood. 2019 Jul 10. pii: blood.2019000402. doi: 10.1182/blood.2019000402. [Epub ahead of print]

PMID:
31292114
3.

"Somatic" and "pathogenic" - is the classification strategy applicable in times of large-scale sequencing?

Baer C, Walter W, Hutter S, Twardziok S, Meggendorfer M, Kern W, Haferlach T, Haferlach C.

Haematologica. 2019 Aug;104(8):1515-1520. doi: 10.3324/haematol.2019.218917. Epub 2019 Jul 4. No abstract available.

4.

DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern.

Cappelli LV, Meggendorfer M, Dicker F, Jeromin S, Hutter S, Kern W, Haferlach T, Haferlach C, Höllein A.

Leukemia. 2019 Jun 17. doi: 10.1038/s41375-019-0502-0. [Epub ahead of print] No abstract available.

PMID:
31209279
5.

RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Leuk Lymphoma. 2019 May;60(5):1334-1336. doi: 10.1080/10428194.2018.1522439. No abstract available.

PMID:
30997874
6.

Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.

Hartmann L, Haferlach C, Meggendorfer M, Kern W, Haferlach T, Stengel A.

Genes Chromosomes Cancer. 2019 Oct;58(10):698-704. doi: 10.1002/gcc.22761. Epub 2019 May 1.

PMID:
30994218
7.

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.

Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze KS, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D.

Genes Chromosomes Cancer. 2019 Oct;58(10):689-697. doi: 10.1002/gcc.22760. Epub 2019 Apr 30.

PMID:
30994215
8.

Impact of 9q deletions on the classification of patients with acute myeloid leukemia.

Balk B, Haferlach T, Meggendorfer M, Kern W, Haferlach C, Stengel A.

J Cancer Res Clin Oncol. 2019 Mar 29. doi: 10.1007/s00432-019-02908-0. [Epub ahead of print] No abstract available.

PMID:
30927073
9.

Impact of assay procedures on detection of MR4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis.

Jeromin S, Eder C, Haferlach C, Haferlach T, Kern W.

Int J Lab Hematol. 2019 Mar 12. doi: 10.1111/ijlh.13004. [Epub ahead of print] No abstract available.

PMID:
30860652
10.

Comprehensive molecular characterization of myeloid malignancies with 9q deletion.

Hartmann L, Haferlach T, Meggendorfer M, Kern W, Haferlach C, Stengel A.

Leuk Lymphoma. 2019 Mar 7:1-3. doi: 10.1080/10428194.2019.1585840. [Epub ahead of print] No abstract available.

PMID:
30844315
11.

European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.

Rack KA, van den Berg E, Haferlach C, Beverloo HB, Costa D, Espinet B, Foot N, Jeffries S, Martin K, O'Connor S, Schoumans J, Talley P, Telford N, Stioui S, Zemanova Z, Hastings RJ.

Leukemia. 2019 Aug;33(8):1851-1867. doi: 10.1038/s41375-019-0378-z. Epub 2019 Jan 29. Review.

PMID:
30696948
12.

Evidence of clonality in cases of hypereosinophilia of undetermined significance.

Pohlkamp C, Vetro C, Dicker F, Meggendorfer M, Kern W, Haferlach C, Haferlach T.

Leuk Lymphoma. 2019 Aug;60(8):2071-2074. doi: 10.1080/10428194.2018.1564825. Epub 2019 Jan 18. No abstract available.

PMID:
30656986
13.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

14.

Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma.

Stratmann JA, von Rose AB, Koschade S, Wendelin K, Köhler F, Heinsch M, Schiller K, Haferlach C, Wattad M, Rieder H, Serve H, Gökbuget N, Steffen B.

Ann Hematol. 2019 Mar;98(3):647-656. doi: 10.1007/s00277-018-03590-x. Epub 2019 Jan 6. Review.

PMID:
30613837
15.

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K; ERIC, the European Research Initiative on CLL.

Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan 2.

16.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.

Haematologica. 2019 May;104(5):955-962. doi: 10.3324/haematol.2018.206797. Epub 2018 Dec 4.

17.

Dreams can come true: the first steps toward a peripheral blood screening test for the early detection of tumors have been taken.

Haferlach C, Haferlach T.

Ann Oncol. 2019 Jan 1;30(1):12-13. doi: 10.1093/annonc/mdy499. No abstract available.

PMID:
30462156
18.

Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Br J Haematol. 2019 Jun;185(5):951-954. doi: 10.1111/bjh.15653. Epub 2018 Nov 20. No abstract available.

PMID:
30460680
19.

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.

Höllein A, Meggendorfer M, Dicker F, Jeromin S, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Blood Adv. 2018 Nov 27;2(22):3118-3125. doi: 10.1182/bloodadvances.2018023432.

20.

Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease.

Stengel A, Jeromin S, Haferlach T, Meggendorfer M, Kern W, Haferlach C.

Haematologica. 2019 May;104(5):e187-e190. doi: 10.3324/haematol.2018.202952. Epub 2018 Nov 8. No abstract available.

21.

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.

Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton LA, Minga E, Scarfò L, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford JC, Stavroyianni N, Belessi C, Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC).

Haematologica. 2019 Feb;104(2):360-369. doi: 10.3324/haematol.2018.195032. Epub 2018 Sep 27.

22.

Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses.

Vetro C, Haferlach T, Jeromin S, Stengel A, Zenger M, Nadarajah N, Baer C, Weissmann S, Kern W, Meggendorfer M, Haferlach C.

Br J Haematol. 2018 Oct;183(1):47-59. doi: 10.1111/bjh.15498. Epub 2018 Jul 18.

PMID:
30022491
23.

Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

L'Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D'Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2018 Oct;32(10):2304. doi: 10.1038/s41375-018-0177-y.

PMID:
29985446
24.

Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.

Ernst T, Busch M, Rinke J, Ernst J, Haferlach C, Beck JF, Hochhaus A, Gruhn B.

Leukemia. 2018 Sep;32(9):2046-2049. doi: 10.1038/s41375-018-0157-2. Epub 2018 Jun 13. No abstract available.

PMID:
29899367
25.

Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm-a comparison of 756 cases.

Baer C, Pohlkamp C, Haferlach C, Kern W, Haferlach T.

Leukemia. 2018 Oct;32(10):2295-2298. doi: 10.1038/s41375-018-0119-8. Epub 2018 Mar 30. No abstract available.

PMID:
29725031
26.

The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms.

Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T.

Haematologica. 2018 May;103(5):e192-e195. doi: 10.3324/haematol.2017.183160. No abstract available.

27.

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.

Höllein A, Jeromin S, Meggendorfer M, Fasan A, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Leukemia. 2018 Oct;32(10):2270-2274. doi: 10.1038/s41375-018-0086-0. Epub 2018 Mar 6. No abstract available.

PMID:
29568097
28.

IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.

Meggendorfer M, Cappelli LV, Walter W, Haferlach C, Kern W, Falini B, Haferlach T.

Leukemia. 2018 May;32(5):1249-1253. doi: 10.1038/s41375-018-0026-z. Epub 2018 Jan 30. No abstract available.

PMID:
29568090
29.

Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2.

Baer C, Muehlbacher V, Kern W, Haferlach C, Haferlach T.

Haematologica. 2018 Aug;103(8):e348-e350. doi: 10.3324/haematol.2017.187302. Epub 2018 Mar 22. No abstract available.

30.

Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing.

Stengel A, Nadarajah N, Haferlach T, Dicker F, Kern W, Meggendorfer M, Haferlach C.

Leukemia. 2018 May;32(5):1229-1238. doi: 10.1038/s41375-017-0002-z. Epub 2018 Feb 26. No abstract available.

PMID:
29479069
31.

MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

L Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2018 Oct;32(10):2152-2166. doi: 10.1038/s41375-018-0033-0. Epub 2018 Feb 22. Erratum in: Leukemia. 2018 Jul 9;:.

32.

Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.

Naumann N, Jawhar M, Schwaab J, Kluger S, Lübke J, Metzgeroth G, Popp HD, Khaled N, Horny HP, Sotlar K, Valent P, Haferlach C, Göhring G, Schlegelberger B, Meggendorfer M, Hofmann WK, Cross NCP, Reiter A, Fabarius A.

Genes Chromosomes Cancer. 2018 May;57(5):252-259. doi: 10.1002/gcc.22526. Epub 2018 Feb 19.

PMID:
29341334
33.

MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.

ĹAbbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2017 Nov 28. doi: 10.1038/leu.2017.337. [Epub ahead of print]

PMID:
29180669
34.

Smoldering Development of Acute Megakaryoblastic Leukemia with Clonal Evolution in an Infant without Down Syndrome.

Schmidt E, Fischer U, Biskup W, Haferlach C, Meisel R, Kuhlen M, Borkhardt A.

Klin Padiatr. 2017 Nov;229(6):352-354. doi: 10.1055/s-0043-113446. Epub 2017 Nov 13. No abstract available.

PMID:
29132167
35.

Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.

Lengfelder E, Görlich D, Nowak D, Spiekermann K, Haferlach C, Krug U, Kreuzer KA, Braess J, Schliemann C, Lindemann HW, Horst HA, Schiel X, Flasshove M, Hecht A, Schnittger S, Schneider S, Wörmann B, Hofmann WK, Berdel WE, Bormann E, Sauerland C, Büchner T, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Eur J Haematol. 2018 Feb;100(2):154-162. doi: 10.1111/ejh.12994. Epub 2017 Dec 4.

PMID:
29114972
36.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

37.

Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.

Stengel A, Kern W, Meggendorfer M, Nadarajah N, Perglerovà K, Haferlach T, Haferlach C.

Leukemia. 2018 Feb;32(2):295-302. doi: 10.1038/leu.2017.239. Epub 2017 Jul 28.

PMID:
28751771
38.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G.

Ann Hematol. 2017 Sep;96(9):1463-1470. doi: 10.1007/s00277-017-3067-x. Epub 2017 Jul 19.

PMID:
28725989
39.
40.

The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.

Rio-Machin A, Gómez-López G, Muñoz J, Garcia-Martinez F, Maiques-Diaz A, Alvarez S, Salgado RN, Shrestha M, Torres-Ruiz R, Haferlach C, Larráyoz MJ, Calasanz MJ, Fitzgibbon J, Cigudosa JC.

Leukemia. 2017 Sep;31(9):2000-2005. doi: 10.1038/leu.2017.194. Epub 2017 Jun 20. No abstract available.

41.

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.

Rinke J, Müller JP, Blaess MF, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross NCP, Hochhaus A, Ernst T.

Leukemia. 2017 Sep;31(9):1936-1943. doi: 10.1038/leu.2017.190. Epub 2017 Jun 19.

PMID:
28626218
42.

Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.

Jann JC, Nowak D, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Fabarius A, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Schlenk R, Bug G, Lübbert M, Ganser A, Germing U, Haferlach C, Hofmann WK, Mossner M.

J Med Genet. 2017 Sep;54(9):640-650. doi: 10.1136/jmedgenet-2017-104528. Epub 2017 Jun 9.

43.

MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Leukemia. 2017 Sep;31(9):1995-1997. doi: 10.1038/leu.2017.180. Epub 2017 Jun 8. No abstract available.

PMID:
28592886
44.

Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse.

Fasan A, Haferlach C, Perglerovà K, Kern W, Haferlach T.

Haematologica. 2017 Jun;102(6):e222-e224. doi: 10.3324/haematol.2016.162206. Epub 2017 Mar 24. No abstract available.

45.

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.

Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Suzuki H, Nagata Y, Sato Y, Kakiuchi N, Matsuo K, Onizuka M, Kataoka K, Chiba K, Tanaka H, Ueno H, Nakagawa MM, Przychodzen B, Haferlach C, Kern W, Aoki K, Itonaga H, Kanda Y, Sekeres MA, Maciejewski JP, Haferlach T, Miyazaki Y, Horibe K, Sanada M, Miyano S, Makishima H, Ogawa S.

Blood. 2017 Apr 27;129(17):2347-2358. doi: 10.1182/blood-2016-12-754796. Epub 2017 Feb 21.

46.

Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia.

Martin-Cabrera P, Jeromin S, Perglerovà K, Haferlach C, Kern W, Haferlach T.

Haematologica. 2017 Apr;102(4):e125-e128. doi: 10.3324/haematol.2016.156844. Epub 2017 Jan 5. No abstract available.

47.

Dynamics of clonal evolution in myelodysplastic syndromes.

Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y, Meggendorfer M, Sanada M, Okuno Y, Hirsch C, Kuzmanovic T, Sato Y, Sato-Otsubo A, LaFramboise T, Hosono N, Shiraishi Y, Chiba K, Haferlach C, Kern W, Tanaka H, Shiozawa Y, Gómez-Seguí I, Husseinzadeh HD, Thota S, Guinta KM, Dienes B, Nakamaki T, Miyawaki S, Saunthararajah Y, Chiba S, Miyano S, Shih LY, Haferlach T, Ogawa S, Maciejewski JP.

Nat Genet. 2017 Feb;49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec 19.

PMID:
27992414
48.
49.

Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Baer C, Dicker F, Kern W, Haferlach T, Haferlach C.

Leukemia. 2017 Jun;31(6):1355-1362. doi: 10.1038/leu.2016.330. Epub 2016 Nov 14.

PMID:
27840426
50.

MYC rearranged B-cell neoplasms: Impact of genetics on classification.

Haberl S, Haferlach T, Stengel A, Jeromin S, Kern W, Haferlach C.

Cancer Genet. 2016 Oct;209(10):431-439. doi: 10.1016/j.cancergen.2016.08.007. Epub 2016 Sep 14.

PMID:
27810071

Supplemental Content

Loading ...
Support Center